The Supreme Court just handed abortion rights advocates a temporary reprieve—but the fight over mifepristone is far from over. In a 5-4 decision on May 14, 2026, the justices blocked a lower court’s attempt to ban telehealth prescriptions of the abortion pill nationwide, preserving access for now. Yet the ruling is less a victory than a pause in a legal battle that could reshape reproductive healthcare in America. And the stakes couldn’t be higher: nearly two-thirds of U.S. Abortions now rely on mifepristone, with a quarter delivered entirely through telehealth. What happens next hinges on a 19th-century law, a divided bench, and a quiet revolution in how Americans access healthcare.
Why This Ruling Matters More Than Dobbs
The Supreme Court’s decision isn’t just about mifepristone—it’s about the future of abortion in America. Since Dobbs overturned Roe v. Wade in 2022, states have scrambled to ban abortion, but telehealth has become a loophole. Louisiana’s lawsuit, which argued the FDA’s telehealth rule violated the 1873 Comstock Act, threatened to close that gap. The act, originally meant to curb “lewd” materials in the mail, now looms as a weapon against reproductive rights.
But here’s the twist: the Comstock Act has been largely dormant for over a century. Why now? Because anti-abortion activists have weaponized it to challenge not just mifepristone, but the entire framework of medication abortion. “This isn’t about the drug’s safety—it’s about control,” says Dr. Ushma Upadhyay, a reproductive health researcher at the University of California, San Francisco. “The real target is autonomy. If they can block telehealth, they can force people back into clinics, where bans can be enforced.”
The Court’s decision to keep the FDA’s rule in place for now is a tactical win, but the legal chessboard is still shifting. The case returns to the 5th Circuit Court of Appeals, which has signaled it may strike down the telehealth rule entirely. If that happens, 13 states with total abortion bans would see their restrictions strengthened—but so would the 27 states where abortion remains legal. Why? Because telehealth isn’t just for banned states. In rural areas, low-income communities, and for people with disabilities, mail-order abortion pills are often the only option.
The Underground Railroad of Abortion Pills
Since Dobbs, telehealth abortion providers like Plan C and Jane’s Due Process have become lifelines. In Texas, where abortion is banned after six weeks, telehealth abortions surged by 500% between 2022, and 2025. In Mississippi, a state with one of the strictest bans, nearly 60% of medication abortions now happen via mail. “We’re seeing a new kind of healthcare desert,” says Dr. Daniel Grossman, director of Advancing New Standards in Reproductive Health (ANSIRH). “People aren’t just crossing state lines—they’re ordering pills online and taking them at home.”
But this isn’t just about convenience. For many, it’s a matter of survival. A 2025 study in JAMA Network Open found that women in banned states who sought telehealth abortions were three times more likely to complete their abortion than those trying to travel to clinics. The data is clear: without telehealth, abortion access would collapse in half the country.
Yet the legal risks are rising. Louisiana’s lawsuit isn’t just about mifepristone—it’s a test case for whether the FDA can regulate abortion pills at all. If the 5th Circuit rules against the agency, other states will follow. Already, Arizona and Florida have filed similar lawsuits. “This is the next front in the culture wars,” warns Elizabeth Nash, policy director at the Guttmacher Institute. “If they can chip away at mifepristone, they’ll go after misoprostol next.”
The Comstock Act: A 150-Year-Old Weapon in a Modern War
The Comstock Act’s revival is a masterclass in legal creativity. Drafted in 1873 to suppress “obscene” materials, it’s been used sparingly—mostly against child pornography. But in 2026, it’s being repurposed to criminalize abortion pills. The irony? The law’s original sponsor, Anthony Comstock, would likely be horrified. His campaign was about morality, not medicine.
Yet the act’s vague language—”any article … For producing abortion”—gives anti-abortion groups ample room to argue that mailing mifepristone is illegal. The FDA’s defense? That the drug is safe, and that the Comstock Act doesn’t apply to FDA-approved medications. But in a court system where Dobbs redefined abortion as a state’s right, the FDA’s authority is now in question.
What’s often overlooked is how the Comstock Act intersects with another relic: the Controlled Substances Act. Louisiana has already reclassified mifepristone as a Schedule III controlled substance—a move that could make it harder to prescribe. If the 5th Circuit agrees, the FDA’s hands may be tied. “This isn’t just about abortion pills,” says Harvard Law Professor Mary Ziegler. “It’s about whether the federal government can regulate healthcare at all. If they win here, the next target could be birth control.”
The Misoprostol Wildcard
While mifepristone dominates headlines, the other abortion pill—misoprostol—remains largely untouched by lawsuits. That’s because misoprostol isn’t approved for abortion; it’s used off-label. And in medicine, off-label use is routine. In fact, 20% of all prescriptions fall into this category, from antidepressants for pain to antibiotics for acne.
But misoprostol’s off-label status isn’t a shield—it’s a vulnerability. Anti-abortion groups have already signaled they’ll target it next. “Misoprostol is just as effective as mifepristone for early abortions,” says Dr. Mitchell Creinin, a professor at the Brown University School of Public Health. “If they take out mifepristone, the next step is to criminalize misoprostol too. And then what? People will turn to even riskier methods.”
There’s a reason this fight feels like a whack-a-mole game. Every time one legal path is blocked, another opens. Already, some providers are exploring WHO-approved protocols for misoprostol-only abortions. But without FDA backing, these methods could face legal challenges too.
What Happens If the 5th Circuit Strikes Down the Rule?
The immediate impact would be catastrophic. In states with bans, telehealth abortions would vanish overnight. But the ripple effects would be national:
- Clinic Overload: States without bans would see a surge in patients traveling for in-person abortions, straining already underfunded healthcare systems.
- Economic Fallout: A 2023 study in Health Affairs estimated that restricting abortion access costs states $1.5 billion annually in lost tax revenue and increased foster care costs.
- Safety Risks: Without telehealth, people may delay abortions or resort to unsafe methods. A 2025 Lancet study found that abortion-related hospitalizations doubled in banned states after Dobbs.
- International Precedent: The U.S. Is the only developed nation where abortion access is so fragmented. If the Comstock Act is used to block medication abortion, it could embolden similar challenges in other countries.
The Supreme Court’s decision to keep mifepristone available via telehealth is a temporary win. But the legal battle isn’t over—and the real question is whether America will let a 150-year-old law dictate modern healthcare. “This isn’t just about pills,” says Nash. “It’s about whether people have the right to make their own medical decisions. And that fight is just beginning.”
What’s next? The 5th Circuit’s ruling could come as early as July. If they strike down the telehealth rule, the Supreme Court will likely hear the case again—setting up a showdown between reproductive rights and a century-old law meant to stop “indecent” mailings. One thing’s certain: the abortion wars aren’t ending. They’re just getting messier.
